Mostrando 661 - 680 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.28s Limitar resultados
  1. 661
  2. 662
    “…The variable clinical outcomes seen in patients with similar HER2 status, given similar treatments, suggests that the effects of amplification of HER2 can be influenced by other genetic changes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
  3. 663
  4. 664
  5. 665
  6. 666
  7. 667
    por Tripathy, Debu
    Publicado 2009
    “…Anti-HER2 monoclonal antibodies have led to significant improvements in survival for both advanced and early stage HER2+ breast cancer, while newer agents, including other antibodies and HER2 receptor tyrosine kinase inhibitors and signal transduction modulators, are also demonstrating clinical activity and represent further opportunities to improve curability and quality of life.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
  8. 668
    por Shah, Sejal, Chen, Beiyun
    Publicado 2010
    “…Human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive factor in breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
  9. 669
  10. 670
    “…Pathologists regularly determined the number of HER2-positive cases (HER2 3+, HER2 2+/amplified or amplified) in their laboratory, and figures were continuously entered into a central website. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  11. 671
    “…Because of excessive cardiotoxicity, their use in combination with trastuzumab has been discouraged in patients with human epidermal growth factor receptor (HER)-2(+) metastatic breast cancer. We sought to describe how this treatment paradigm influenced the use of anthracyclines in this patient setting. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  12. 672
    “…The relationship between abnormal HER2 expression and cancer is important in cancer therapeutics. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  13. 673
  14. 674
  15. 675
    “…She was treated with dopamine agonists for 10 years and after cessation of therapy her prolactin levels remain normal. The nasopharyngeal mass remained unchanged over time and there were no signs of hypopituitarism. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 676
  17. 677
  18. 678
    “…Approximately 20%–25% of patients with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, resulting in an overexpression of the HER2 receptor. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  19. 679
    “…Our goal in these analyses was to use genomic features from a test set of primary breast tumors to build an integrated transcriptome landscape model that makes relevant hypothetical predictions about the biological and/or clinical behavior of HER2-positive breast cancer. We interrogated RNA-Seq data from benign breast lesions, ER+, triple negative, and HER2-positive tumors to identify 685 differentially expressed genes, 102 alternatively spliced genes, and 303 genes that expressed single nucleotide sequence variants (eSNVs) that were associated with the HER2-positive tumors in our survey panel. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  20. 680
Herramientas de búsqueda: RSS